Psoriasis Risk in Patients With Atopic Dermatitis Treated With Dupilumab
The results of this cohort study suggest that patients with AD who were prescribed dupilumab exhibited a higher relative risk of developing psoriasis compared with those receiving other systemic agents. Given an estimated number needed to harm of 94, the absolute risk may have limited clinical relevance and should be weighed against dupilumab's established efficacy in treating AD.
Authors
- Teng‐Li Lin (ORCID: https://orcid.org/0000-0002-0639-3533)
- Yi‐Hsuan Fan
- Yi–Ju Chen (ORCID: https://orcid.org/0000-0001-8932-5095)
- Chao‐Kuei Juan (ORCID: https://orcid.org/0000-0002-8846-0831)
- Chun-Ying Wu (ORCID: https://orcid.org/0000-0003-4207-2312)
- Kuo-Sheng Fan
Institutions
- National Yang Ming Chiao Tung University (TW)
- National Chung Hsing University (TW)
- China Medical University (TW)
- Taipei Veterans General Hospital (TW)
- Taichung Veterans General Hospital (TW)
- Chung Shan Medical University Hospital (TW)
Publication Details
- Journal
- JAMA Dermatology
- Published
- 2025-06-18
- DOI
- https://doi.org/10.1001/jamadermatol.2025.1578
- Citations
- 17
- Primary Topic
- Dermatology and Skin Diseases
- Type
- article
- Field-Weighted Citation Impact
- 34.08